DWP
AUPH icon

Daymark Wealth Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Daymark Wealth Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$57.1K – 513
2024
Q2 		$57.1K Hold
10,000
– – ﹤0.01% 492
2024
Q1 		$50.1K Hold
10,000
– – ﹤0.01% 427
2023
Q4 		$89.9K Hold
10,000
– – 0.01% 396
2023
Q3 		$77.7K Hold
10,000
– – 0.01% 374
2023
Q2 		$96.8K Buy
+10,000
New +$104K 0.01% 370

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Daymark Wealth Partners's AUPH Position: Q3 2024 in Review

Daymark Wealth Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2024, closing a stake of 10,000 shares — an estimated $57.1K sold.

Daymark Wealth Partners first reported a position in AUPH in Q2 2023 and held it in 5 quarters. The position peaked at $96.8K in Q2 2023. 183 funds tracked by Wall St. Rank hold AUPH as of Q3 2024.

  • Daymark Wealth Partners reported no remaining Aurinia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Daymark Wealth Partners sold 10,000 Aurinia Pharmaceuticals shares in Q3 2024, an estimated $57.1K.
  • Daymark Wealth Partners first reported a position in Aurinia Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Daymark Wealth Partners's Aurinia Pharmaceuticals position peaked at $96.8K in Q2 2023.
  • 183 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2024.

Based on Daymark Wealth Partners's 13F filing for Q3 2024, filed 8 Oct 2024.